1036738-12-1

Basic information

• Product Name: 2,4,6-Trichloro-pyrido[3,2-d]pyrimidine
• Synonyms: 2,4,6-Trichloro-pyrido[3,2-d]pyrimidine
• CAS NO: 1036738-12-1
• Molecular Formula: C₇H₂Cl₃N₃
• Molecular Weight: 234.46988
• Mol File: 1036738-12-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,4,6-Trichloro-pyrido[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-Trichloro-pyrido[3,2-d]pyrimidine(1036738-12-1)
• EPA Substance Registry System: 2,4,6-Trichloro-pyrido[3,2-d]pyrimidine(1036738-12-1)

Safety Data

• Hazardous Substances Data: 1036738-12-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4,6-Trichloro-pyrido[3,2-d]pyrimidine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2,4,6-Trichloro-pyrido[3,2-d]pyrimidine is utilized as a precursor for the production of agrochemicals, such as pesticides and herbicides. Its trichlorinated pyridine structure contributes to the effectiveness of these products in controlling pests and weeds.
Used in Organic Synthesis:
2,4,6-Trichloro-pyrido[3,2-d]pyrimidine serves as a valuable building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications.
Used in Material Development:
2,4,6-Trichloro-pyrido[3,2-d]pyrimidine is used as a component in the development of new materials, leveraging its unique structural properties to enhance the performance and functionality of various materials.
Used as a Research Tool:
2,4,6-Trichloro-pyrido[3,2-d]pyrimidine is employed as a research tool in the study of pyridine-containing compounds, aiding scientists in understanding their properties, reactivity, and potential applications in various fields.

Upstream product

• 897360-38-2 6-chloropyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 175358-01-7 3-amino-6-chloro-pyridine-2-carboxylic acid amide 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 866807-26-3 methyl 3-amino-6-chloropicolinate 

Downstream Products

• 2454244-02-9 methyl 4-(trans-4-((6-(cyanomethyl)-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrido[3,2-d]pyrimidin-4-yl)amino)cyclohexyl)piperazine-1-carboxylate 
• 1203653-35-3 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N₄-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1318780-21-0 N-(4-(1H-1,2,4-triazol-1-yl)benzyl)-6-chloro-4-(1-methylcyclopropoxy)pyrido[3,2-d]pyrimidin-2-amine 
• 1203652-46-3 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(3-(methylsulfonyl)phenyl)-N₄-(1-(trifluoromethyl)cyclopropyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1318780-19-6 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-chloro-N₄-(1-(trifluoromethyl)cyclopropyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1318780-18-5 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-chloro-N₄-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1352577-51-5 C₃₂H₃₀F₉N₇O₃S 
• 1318780-12-9 N-tert-butyl-3-((6-chloro-4-(2,2,2-trifluoroethylamino)pyrido[3,2,d]pyrimidin-2-ylamino)methyl)-5-(trifluoromethyl)benzenesulfonamide 
• 1203652-17-8 4-((6-(4-methoxy-3-(methylsulfonyl)phenyl)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-2-ylamino)methyl)benzenesulfonamide 
• 1036736-85-2 4-{[6-(6-fluoro-pyridin-3-yl)-4-(2,2,2-trifluoro-ethylamino)-pyrido[3,2-d]pyrimidin-2-ylamino]-methyl}-benzenesulfonamide 
• 1318780-06-1 N-(4-(2-(4-sulfamoylbenzylamino)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)cyclopropanecarboxamide 
• 1318780-05-0 4-((4-(1-cyanocyclopropylamino)-6-(6-fluoropyridin-3-yl)pyrido[3,2-d]pyrimidin-2-ylamino)methyl)benzenesulfonamide 
• 1036738-25-6 4-((6-chloro-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-2-ylamino)methyl)benzenesulfonamide 
• 1318780-04-9 4-((6-(4-(1H-1,2,4-triazol-1-yl)phenyl)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-2-ylamino)methyl)benzenesulfonamide 

Relevant articles and documents

Preparation method of novel substituted pyridine pyrimidine compound

The invention belongs to the field of pharmaceutical and chemical industry, and provides a preparation method of a novel substituted pyridine pyrimidine compound. The pyridine pyrimidine compound is of great significance to medical research and new drug development. The problem that an amide compound is easily destroyed by strong alkalis in a synthesis process under a high temperature condition issolved, and meanwhile the problem that a pyrimidine 4-amino group is difficult to react to synthesize amide due to poorer amino activity is solved. Moreover, a two-step reaction for reducing a nitrogroup into an amino group and hydrolyzing cyano group into the amide group is completed in a one-step reaction, thereby simplifying the reaction flow. The invention provides a preparation method of the compound. The compound provides important support for the application of the compound in the field of new drug development in the future in terms of synthesis conditions, methods and processes.

Discovery and in vivo effects of novel human natriuretic peptide receptor A (NPR-A) agonists with improved activity for rat NPR-A

Natriuretic peptide receptor A (NPR-A) agonists were evaluated in vivo by optimizing the structure of quinazoline derivatives to improve agonistic activity for rat NPR-A. A 1,4-Cis-aminocyclohexylurea moiety at 4-position and hydroxy group of D-alaninol at 2-position on the quinazoline ring were found to be important factors in improving rat NPR-A activity. We identified potent quinazoline and pyrido[2,3-d]pyrimidine derivatives against rat NPR-A, with double-digit nanomolar EC50 values. The in vivo results showed that compound 56b administered at 1.0 mg/kg/min significantly increased plasma cGMP concentration and urine volume in rats. We discovered novel potent NPR-A agonists that showed agonistic effects similar to those of atrial natriuretic peptide.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

Optimization of pharmacokinetics through manipulation of physicochemical properties in a series of HCV inhibitors

A novel series of HCV replication inhibitors based on a pyrido[3,2-d]pyrimidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of comp

2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS

Pyrido(3,2-d)pyrimidine derivatives represented by the structural formuia (Ia): wherein, R1, R2 and R3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro

PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS

Pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (I), wherein: R4 is hydrogen, and R1, R2 and R3 together provide a specific substitution pattern, pharmaceutical acceptable addition salt